First approval of ADCs by other regulatory agencies
| Drug | Target | Indication | Country | Approval year | Sponsor |
|---|---|---|---|---|---|
| Cetuximab sarotalocan | EGFR | Head and neck cancer | Japan | 2020 | RakutenMedical |
| Disitamab vedotin | HER2 | HER2+ gastric carcinoma | China | 2021 | RemeGen |
ADCs: antibody-drug conjugates; EGFR: epidermal growth factor receptor; HER2: human EGFR 2